A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
SAN FRANCISCO -- Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG), topline data from ...
The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...
The complement system, a central component of innate immunity, exerts a dual influence on cerebral ischaemia, driving both acute tissue injury and later reparative processes. Following arterial ...
The FDA granted accelerated approval to iptacopan (Fabhalta) for primary immunoglobulin A (IgA) nephropathy, a rare progressive disease where the immune system attacks the kidneys, Novartis announced ...
Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement inhibitor ADX-097, paying $7 million upfront for an asset that forms the centerpiece of its new rare kidney disease ...
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Phase 1 clinical trial of AMG 340, a prostate-specific membrane antigen (PSMA)-targeted T-cell engager with a novel low-affinity CD3 binding domain designed to mitigate toxicity for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results